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Abstract
Although phototherapy was introduced as early as 1950’s, the potential biological effects of
bilirubin photoisomers (PI) generated during phototherapy remain unclear. The aim of our
study was to isolate bilirubin PI in their pure forms and to assess their biological effects in
vitro. The three major bilirubin PI (ZE- and EZ-bilirubin and Z-lumirubin) were prepared by
photo-irradiation of unconjugated bilirubin. The individual photoproducts were chromato-
graphically separated (TLC, HPLC), and their identities verified by mass spectrometry. The
role of Z-lumirubin (the principle bilirubin PI) on the dissociation of bilirubin from albumin
was tested by several methods: peroxidase, fluorescence quenching, and circular dichro-
ism. The biological effects of major bilirubin PI (cell viability, expression of selected genes,
cell cycle progression) were tested on the SH-SY5Y human neuroblastoma cell line. Lumi-
rubin was found to have a binding site on human serum albumin, in the subdomain IB (or at
a close distance to it); and thus, different from that of bilirubin. Its binding constant to albu-
min was much lower when compared with bilirubin, and lumirubin did not affect the level of
unbound bilirubin (Bf). Compared to unconjugated bilirubin, bilirubin PI did not have any
effect on either SH-SY5Y cell viability, the expression of genes involved in bilirubin metabo-
lism or cell cycle progression, nor in modulation of the cell cycle phase. The principle biliru-
bin PI do not interfere with bilirubin albumin binding, and do not exert any toxic effect on
human neuroblastoma cells.
Introduction
Phototherapy as a treatment option for neonatal hyperbilirubinemia was first used by Cremer
and co-workers in the 1950's [1]. This technique is based on the fact that blue-green light con-
verts bilirubin into more polar derivatives. Configurational and structural photoisomers (PI),
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ZE- and EZ-bilirubins, lumirubin (also called cyclobilirubin) (Fig 1) [2–4], as well as propent-
dyopents and other oxidation products [5,6], can be relatively easily excreted from the body.
Although phototherapy for neonatal hyperbilirubinemia is accepted as the 'gold standard' of
treatment, it may be accompanied with side effects such as impairment of thermoregulation,
Fig 1. Bilirubin and its photoderivatives. (A) Z,Z-Bilirubin IXα. (B) Z,E-Bilirubin IXα. (C) E,Z-Bilirubin IXα.
(D) Z-Lumirubin IXα.
doi:10.1371/journal.pone.0148126.g001
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mineral dysbalance [7], and direct genotoxic effects on lymphocyte DNA [8]. This might also
be one of the reasons for the increased prevalence of allergic conditions reported in these new-
borns [9]. In addition, intensive phototherapy in very low birth-weight newborns has been
associated with increased risk of ileus [10]; also surprisingly by increased mortality, as demon-
strated in the Collaborative Phototherapy Trial, as well as the NICHD Neonatal Network Trial
[11,12].
The neurotoxicity of bilirubin is directly associated with the concentration of the fraction
unbound to albumin (or other solubilizing substances), which is called Bf (bilirubin free)
[13,14]. Bf is critically dependent on the presence of compounds that are potentially competing
with bilirubin in binding to albumin [15]. Nothing is known about whether bilirubin PI may
affect the bilirubin-albumin interaction. Previous studies on the biological effects of bilirubin
photoproducts [16–23] suffered from a major limitation (insufficient purity of the bilirubin
photoproducts), as well as inconsistent study designs. Thus, there is still uncertainty on the
potential toxicity of bilirubin breakdown products not only for the central nervous system, but
also other organs.
Therefore, the aim of the current study was to isolate and characterize pure forms of biliru-
bin PI; and then to assess their potential effects on bilirubin-albumin binding, as well as their
possible biological effects in vitro using the neuroblastoma cell line SH-SY5Y.
Materials and Methods
Chemicals
The bilirubin (AppliChem, Darmstadt, Germany) was purified before use, according to McDo-
nagh and Assissi [24]. The chloroform and di-n-octylamine were purchased from Sigma (MO,
USA). The methanol was fromMerck (Darmstadt, Germany), and ammonia from Penta
(Czech Republic).
Because of light-sensitivity of bilirubin and bilirubin PI, all procedures were carried out
under dim light in aluminium wrapped flasks. Evaporation was performed under vacuum and
stream of nitrogen.
Preparation of PI
The pure bilirubin photoderivatives were prepared as previously described [25–27] with a
slight modification of the original protocol. Briefly, bilirubin (100 mg) was dissolved in slightly
basified methanol (1% NH3 solution in methanol); the solution underwent 90 minutes of
photo-irradiation using a Lilly phototherapeutical device (TSE, Czech Republic), composed of
a field of LEDs emitting light (wavelength range = 430–500 nm with a broad peak between 445
and 474 nm (width at half max) with a maximal spectral irradiance of 100 μW/cm2/nm corre-
sponding to the total irradiance of 3.1 mW/cm2. The sample was then evaporated under vac-
uum, dissolved in pure methanol, decanted from the residual bilirubin, and re-evaporated. The
residue of bilirubin PI was protected from light, and stored at -20°C until use.
Thin layer chromatography
The residue after photo-irradiation was dissolved in a small amount of methanol:chloroform
(1:1, v/v), and separated by thin layer chromatography (200 x 200 x 0.25 mm Kieselgel 60 TLC
plates [Merck, Darmstadt, Germany]; the mobile phase = chloroform:methanol:water, 40:9:1,
v/v/v). During the first chromatography, the mixture of bilirubin derivatives was separated into
8 major bands, which were extracted using the mobile phase, evaporated to dryness, and then
re-chromatographed using the same conditions. The individual separated compounds were re-
Biological Effects of Bilirubin Photoisomers
PLOS ONE | DOI:10.1371/journal.pone.0148126 February 1, 2016 3 / 16
extracted, the solvent evaporated, and the isolated compounds were stored at -20°C until used.
The isolated compounds 1 and 7, corresponding to ZE/EZ-bilirubins and lumirubin, as verified
by HPLC [28,29] (Figs 2 and 3, also see Results), in a 1:1 ratio, were used for functional and
biological studies as being representative of the principle bilirubin PI.
High-performance liquid chromatography analyses
The HPLC analyses were performed using an Agilent 1200 system (CA, USA) with a diode-
array detector. The method was a modification of that by McDonagh et al. [28,29]. The mobile
phase consisted of 0.1 M di-n-octylamine acetate in methanol and water; the stationary phase
was represented by a Poroshell 120, SB-C18 column (4.6 x 100 mm, 2.7 μm; Agilent, CA,
USA). Samples were prepared by mixing 20 μl of bilirubin solution with 180 μl of ice-cold 0.1
M di-n-octylamine acetate in methanol, then vortexed and centrifuged to eliminate proteins.
Twenty μl of the prepared sample was injected onto the column.
Spectrophotometry
The absorption spectra of pure bilirubin PI were measured using a Lambda 25 spectrophotom-
eter (Perkin Elmer, USA) in the spectral range from 200 to 900 nm. Samples for analyses were
diluted in pure methanol, and measured against methanol as the blank.
Mass Spectrometry
Mass spectra were measured by using an Escuire 3000 mass spectrometer (Bruker Daltonics,
Germany) coupled with electrospray ionization. All samples for MS analysis, dissolved in
methanol, were injected directly on MS and measured in a negative mode. The masses were
scanned in the range between 50 and 800 m/z. The capillary exit was set at -106.7 V.
Estimation of binding constant by fluorescence quenching
A fluorescence quenching method was used for measurement of either lumirubin-albumin or
bilirubin-albumin interactions, as well as their binding constants [30]. The determination is
based on the fact that bile pigments do not emit any fluorescence; on the other hand, human
serum albumin (HSA) contains a tryptophan residue (Trp-214) in the subdomain IIA, which is
responsible for its fluorescence. Thus, the binding constant for bilirubin and lumirubin to HSA
was determined by quenching of the intrinsic Trp fluorescence.
For the Ka determination, formula (1) was used:
Ka ¼ F0  F
F CL  n F0FF0 Cp
  ð1Þ
- where F0 was the ﬂuorescence of HSA without a quencher, F the ﬂuorescence of HSA with a
quencher, CL was the quencher concentration, and CP was the concentration of HSA.
The effect of cooperative binding of lumirubin and bilirubin was also studied, and the
results were compared to the Ka obtained in the systems with biliverdin and gossypol, which
served as a displacing agent of bilirubin from HSA [31,32].
Characterization of the bile pigment albumin binding sites by circular
dichroism (CD) spectroscopy
Unbound pigments were dissolved in 0.1 mol/L NaOH and mixed with the HSA solution in
PBS (pH 7.4) at the molar ratio [pigment]/[HSA] = 1/1, the concentration of the pigment was
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1.5 x 10−5 mol/L. Bilirubin did not undergo aggregation, as verified by spectrophotometry [33].
CD spectra were obtained using a J-810 spectropolarimeter (Jasco, Japan) and analyzed as
described elsewhere [34]. The method is based on the fact that the unbound pigment does not
give any CD signal, and monitoring of their CD intensity provides information about their co-
binding or displacement and localization in the albumin subdomains. For determination of the
subdomain for lumirubin binding two compounds were used, hemin and bilirubin, as marker
ligands for subdomain IB and IIA, respectively [31,35].
Fig 2. Compounds produced by bilirubin phototherapy. (A) TLC plate after first chromatography. (B)
Most important compounds 1 and 7 were separated by re-chromatography from the 1st (upper panel), and 7th
zone (lower panel). UCB, unconjugated bilirubin.
doi:10.1371/journal.pone.0148126.g002
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Determination of Bf
The effect of bilirubin PI on Bf levels was studied by a peroxidase method [36]. Briefly, the
standard stock solution of horseradish peroxidase (HRP) was made (1 mg/ml), which was
Fig 3. HPLC chromatograms of isolated bilirubin PI. (A) HPLC chromatogram of band 1 from TLC—
mixture of ZE/EZ-bilirubins; peak 1 = EZ-bilirubin, peak 2 ZE-bilirubin. (B) HPLC chromatogram of band 7
from TLC—Z-lumirubin.
doi:10.1371/journal.pone.0148126.g003
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diluted by PBS to different concentrations ranging from 1:2 to 1:100. For each enzyme dilution
the Kp value (oxidation constant of bilirubin) was determined. For enzyme standardization (Kp
constant determination, also see below), the solution of bilirubin in PBS without albumin was
used (bilirubin concentrations were between 1 and 3 μM). Bilirubin absorbance was measured
at 440 nm (Beckman Coulter DU-730 spectrophotometer, CA, USA). Afterwards, 5 μl of H2O2
and 10 μl of HRP were added, the solution was slightly mixed, and the decrease of absorbance
at 440 nm in 60 s was measured. The Kp constant was counted according to Kp calculation for-
mula (2):
Kp ¼
V0
½Bf   ½HRP ð2Þ
- where Kp = constant for oxidation of bilirubin, and V0 = the initial oxidation velocity
(expressed as ΔAbs/min).
The measurements of Bf in PBS-containing albumin or in complete culture medium was
performed with enzymes whose Kp values were similar (in our experimental setup, enzyme
dilutions of 1:2, 1:3, and 1:4 were used). We first determined the bilirubin concentration corre-
sponding (under the conditions used) to 140 nM (approximately 24 μM bilirubin). Then, we
studied whether Bf is affected by the addition of increasing concentrations of bilirubin PI (15%
and 30% of total bilirubin concentrations, respectively, based on the fact that as much as 30%
decrease of total serum/plasma bilirubin concentrations can be achieved during phototherapy
of neonatal jaundice [37]). A mixture of ZE/EZ-bilirubins and Z-lumirubin was used for these
studies. To assess the possible effect of solvent on Bf concentration, DMSO was used in the
same concentration as for dissolving of bilirubin PI. To check the stability of bilirubin PI, con-
centrations of bilirubin IXα, and EZ/ZE-bilirubins as well as Z-lumirubin after 1 and 24 hrs in
the incubation medium were analysed by HPLC method (see above). Whereas all studied pig-
ments did not change their concentrations after 1 hr and bilirubin IXα, and EZ/ZE-bilirubins
were stable also after 24 hrs under conditions used, concentrations of Z-lumirubin decreased to
31% after 24 hrs.
Cell culture studies
The SH-SY5Y human neuroblastoma cell line was used for the in vitro studies (ATCC, Manas-
sas, VA, USA). Authentication of the cell line was confirmed by independent laboratory (Gen-
eri Biotech, Czech Republic). The cells were tested for Mycoplasma contamination using the
MycoAlert luminescence test (Lonza, Switzerland). Cells were cultured in a mixture of MEM
Eagle and Ham’s F12 media (1:1, v/v), containing 15% of fetal bovine serum, in 75 cm2 culture
flasks, at 37°C, in a 5% CO2 atmosphere. For functional tests, cells were seeded at a concentra-
tion of 50,000 cells per 1 cm2.
Cell viability analyses
The effect of bilirubin (24 μM), pure bilirubin PI (5%, 15%, and 30% of bilirubin PI in complete
culture media), and the combination of bilirubin with bilirubin PI on cell viability was analyzed
by both MTT (Sigma, Germany) as well as by luminescent CellTiter-Glo (Promega, USA) tests,
using a Sunrise Microplate Reader (Tecan, Austria) and Synergy 2 Multi-mode Microplate
Reader (BioTek, USA), respectively.
Gene expression studies
The effect of bilirubin and bilirubin PI (24 μM bilirubin (corresponding to 140 nM Bf), 15%
bilirubin PI, and a mixture of bilirubin and 15% PI) on the expression of genes involved in
Biological Effects of Bilirubin Photoisomers
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heme catabolism and in the regulation of the cell cycle (Table 1) was investigated in SH-SY5Y
cells exposed to pigments for 1 and 24 hrs, respectively. Briefly, total RNA was isolated in TriR-
eagent (Sigma-Aldrich, St Louis, MO, USA) according to the manufacture's protocol and
stored at -80°C until analysis. RNA quantity and purity were evaluated spectrophotometrically
at 260 nm, and RNA integrity was evaluated by agarose gel electrophoresis. Retrotranscription
of total RNA (1 μg) was performed with an iScript cDNA Synthesis Kit (Bio-Rad Laboratories,
Hercules, CA, USA) according to the manufacturer's instructions. The final cDNA was con-
served at -20°C until used. The primers for the targeted genes and the two housekeeping genes
[hypoxanthine-guanine phosphoribosyltransferase (Hprt1) and glyceraldehydes 3-phosphate
dehydrogenase (Gapdh)] were designed using Beacon Designer 2.0 software (PREMIER Bio-
soft International, Palo Alto, CA, USA). The quantitative analysis of gene expression was
performed by real-time PCR. The reaction was performed on 25 ng of cDNA, with the corre-
sponding gene-specific sense and anti-sense primers (250 nM, all genes) with iQ SYBER Green
Supermix in an I-Cycler iQ thermocycler (Bio-Rad Laboratories, Hercules, CA, USA). The
thermal cycler conditions consisted of 3 min at 95°C; plus 40 cycles each at 95°C for 20 s, 60°C
for 20 s, and 72°C for 30 s. A melting curve analysis was performed to assess product specific-
ity. The relative quantification was made using iCycler iQ software, version 3.1 (Bio-Rad Labo-
ratories, Hercules, CA, USA), by the ΔΔCt method, taking into account the efficiencies of the
individual's genes, and normalizing the results to the two housekeeping genes [38,39]. The lev-
els of mRNA were expressed relative to a reference sample. The results are expressed as the
mean ± SD.
Heme oxygenase activity determination
The activity of heme oxygenase (HMOX) was measured as described previously [40]. In brief,
culture media harvested from SH-SY5Y batches were added to CO-free, septum-sealed vials.
CO released into the vial headspace was quantified using gas chromatography with a reduction
gas analyzer (Peak Laboratories, Mountain View, CA, USA).
Flow cytometry
Cells for flow cytometry analyses were treated with bilirubin (24 μM corresponding to 140 nM
Bf), bilirubin PI (15%), and a combination of bilirubin and PI for 1 and 24 hrs. At the end of
the treatment the medium was aspired, the cells were washed twice with PBS, then fixed by
adding 5 ml of cold (-20°C) 80% ethanol drop-wise under constant gentle vortexing. After
Table 1. List of genes used for gene expression analyses.
Gene Accession Number Forward Reverse Ampl Lenght Efﬁciency
CFTR/MRP (ABCC1) NM_004996.3 tgatggaggctgacaagg gcggacacatggttacac 127 99.20
MDR/TAP (ABCB1) NM_000927 tgctcagacaggatgtgagttg aattacagcaagcctggaacc 122 92.90
HMOX1 NM_002133.2 atgccccaggatttgtca cccttctgaaagttcctcat 95 95.00
HMOX2 NM_001127204.1 tgagtataacatgcagatattca ccatcctccaaggtctct 75 92.40
BLVRA NM_000712 cgttcctgaacctgattg aaagagcatcctccaaag 87 96.00
CyclinD1 XM_006718653.1 acagatgtgaagttcatt tagtaggacaggaagttg 110 96.50
CyclinE1 NM_001238.2 agcccttgggacaataatg cggtcatcatcttctttg 76 94.50
GAPDH NM_002046 tcagccgcatcttcttttg gcaacaatatccactttaccag 146 103.00
HPRT1 NM_000194 acatctggagtcctattgacatcg ccgcccaaagggaactgatag 193 105.00
HPRT1 and GAPDH were used as house-keeping genes.
doi:10.1371/journal.pone.0148126.t001
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centrifugation (310 x g; RT; 6 min), the sediments were re-suspended in 1 ml of staining solu-
tion in PBS containing 0.1% v/v Triton X-100, 20 μg/ml propidium iodide (PI), and 0.2 mg/ml
DNAse free RNaseA. Samples were incubated in the dark for 30 min at RT, and subjected to
FACS analysis (cytometer BD FACSCalibur TM; and CellQuest software, BD Biosciences, San
Jose, CA). Data were collected for 10,000 events per sample.
Statistical analyses
Data are presented as the median and 25–75% range. Differences between variables were evalu-
ated by the Mann-Whitney Rank Sum test. Differences were considered statistically significant
when p-values were less than 0.05. Statistical analyses were performed using Prism 6 software
(GraphPad, CA, USA).
Results
The isolation of bilirubin PI
Photo-exposure of unconjugated bilirubin, under the conditions defined above, lead to the gen-
eration of 18 different PI (Fig 2). These compounds were further characterized by HPLC, UV/
VIS spectrophotometry, and mass spectrometry to check for their purity and identity.
Out of these 18 individual substances, several were clearly identified (unconjugated biliru-
bin, biliverdin, ZE/EZ-bilirubin, and lumirubin); the others are likely to represent unstable,
oxidized, and as yet undefined intermediates. Pigments 1 and 7 (Fig 2), identified as ZE/EZ-bil-
irubins and lumirubin (the principal bilirubin PI), were used for further functional studies.
(Figs 2 and 3).
Effect of bilirubin PI on the bilirubin-albumin binding
To investigate whether bilirubin PI might affect Bf levels, we directly analyzed this effect by
measuring Bf using a peroxidase method. The addition of 3.6 and 7.2 μM of bilirubin PI (corre-
sponding to 15% and 30% of total bilirubin concentration, respectively) had no effect on the Bf
concentration (Fig 4).
To a solution with 140 nM Bf concentration (approximately 24 μM bilirubin), bilirubin PI
were added in increasing concentrations (15% and 30%); the resultant bar was constructed
from the difference between the decrease of absorbance after addition of bilirubin PI or DMSO
to the bilirubin solution. n = 6 for each group.
These data were further confirmed by the study of lumirubin-albumin binding (Table 2),
where a fluorescence quenching method was used for the estimation of the albumin binding
constant (Ka) for bilirubin and lumirubin. Lumirubin had a significantly lower Ka compared
to bilirubin (Table 2). Its effect was comparable with that of biliverdin, which does not affect
bilirubin binding to serum albumin because their high-affinity binding sites are located in two
different subdomains (IB for biliverdin, and IIA for bilirubin). In line with this conclusion, the
bilirubin-albumin binding constant was notably affected by gossypol, a displacer of bilirubin
from HSA [31,32]. Therefore, lumirubin only moderately affected bilirubin binding to HSA
(Table 2).
The results of the CD analyses further supported this conclusion. Bilirubin was found to be
bound to a high-affinity site inducing the CD positive couplet [460(+)/410(-) nm] that is char-
acteristic for the bound P-conformer of bilirubin (see Fig 5, left panel). In the complexes with
HSA, bilirubin shows an absorption maximum at 475 nm, which is shifted closer to the red
spectrum compared to the unbound pigment in solution (440 nm; as can be seen on Fig 5, left
panel). In contrast, CD spectrometric analysis of the lumirubin-albumin complex revealed that
Biological Effects of Bilirubin Photoisomers
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lumirubin has one binding site on HSA with right-helical conformation (it is also a P-
conformer) of the bound pigment [weak positive couplet 445(+)/407(-) nm; Fig 5, left panel].
The obtained lumirubin-HSA complex had also a slight red-shifted absorption band with the
maximum at 445 nm, compared to unbound lumirubin that absorbed at 430 nm.
To clarify the albumin domain that binds lumirubin, three different complexes of HSA and
the marker ligand were used (Fig 5, right panel). The HSA-bilirubin system (green line, Fig 5A)
was first compared with that of HSA-lumirubin (blue line). The resulted signal (black line) of
the lumirubin-(HSA-bilirubin) complex is not the sum of lumirubin-HSA and bilirubin, and
has indicating that the bilirubin and lumirubin binding sites are not independent. Lumirubin is
bound close to the bilirubin high-affinity binding site, and it is able to affect bilirubin binding
to HSA. In the HSA-hemin system (CD spectrum in green, Fig 5B), the addition of lumirubin
did not induce the positive couplet characteristic for lumirubin bound to HSA (Fig 5B). It con-
firms that lumirubin and hemin bind to the same binding site. The binding site of lumirubin is
localized in the subdomain IB [35] (or at a close distance to it), so the hemin presented there
hindered the lumirubin binding. However, in the case where both bilirubin and hemin were
bound to HSA (green spectrum in Fig 5C), the addition of lumirubin led to a moderate
decrease of the bilirubin signal. This strongly suggests that the binding of lumirubin moder-
ately affects bilirubin binding to HSA, and that the lumirubin binding site is localized close to
the hemin and bilirubin binding sites.
Fig 4. Effect of bilirubin PI on Bf concentrations.
doi:10.1371/journal.pone.0148126.g004
Table 2. The binding constant for the ligand-HSA complexes.
bilirubin-HSA lumirubin-HSA bilirubin-(HSA-biliverdin) bilirubin-(HSA- gossypol) bilirubin-(HSA-lumirubin)
Ka [M-1] (1.8±0.3)108 (9.3±0.8)105 (1.1±0.4)108 (1.4±0.2)105 (8.7±1.3)107
HSA, human serum albumin; Ka, the binding constant
doi:10.1371/journal.pone.0148126.t002
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Collectively, our data indicate that lumirubin only negligibly influences bilirubin binding to
albumin. Although lumirubin binds to albumin, its binding has a much lower affinity and
occurs at a different binding site. Nevertheless, the binding sites for bilirubin and lumirubin are
at a close distance to one another, and these binding sites are not independent.
The effect of bilirubin PI on SH-SY5Y cell viability
The short-term exposure (60 min) of bilirubin or its PI did not have any effect on cell viability
(data not shown). However, cell viability was significantly reduced after the 24 or 48 hr cell
treatments with bilirubin, and this effect further increased after 48 hours of exposure (Fig 6A
and 6B, respectively). In contrast, bilirubin PI did not affect cell viability, even after 48 hr expo-
sure and a high concentration used (30%) (Fig 6A and 6B).
Fig 5. (Left panel) CD and UV/Vis absorption spectra of unbound (broken line), lumirubin (blue),
bilirubin (red), and their complexes with HSA (full line). Pigment/HSAmolar ratio = 1/1; c (pigment) = 1.5
x 10−5 mol/L. Bilirubin was dissolved in 0.1 mol/L NaOH and mixed with the HSA solution in PBS (pH 7.4) at
the molar ratio [pigment]/[HSA] = 1/1, the concentration of the pigment was 1.5 x 10−5 mol/L. (Right panel)
Effect of lumirubin on HSA binding with different marker ligands: bilirubin (A), hemin (B), and with
both bilirubin and hemin (C). CD spectra of HSA-marker ligand are shown in green, lumirubin-HSA
complex and lumirubin bound to the complex HSA-marker ligand are shown as blue and black full lines,
respectively. Black arrows show the changes in signals after formation of lumirubin-(marker ligand-HSA)
complexes. Lumirubin/HSA/marker molar ratio = 1/1/1.
doi:10.1371/journal.pone.0148126.g005
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The effect of bilirubin and bilirubin PI on expression of genes involved in
the heme catabolic pathway and cell cycle progression
Bilirubin is the final product of the heme catabolic pathway, and its formation is under the con-
trol of both HMOX and biliverdin reductase (BLVRA). Since these enzymes are protective
tools of the organism against increased oxidative stress [41,42] (as well as responsible for biliru-
bin production), we investigated the effects of PI on the expression of these genes.
The expressions of bothHMOX1 and HMOX2 were significantly increased after 1 hr of
exposure to toxic concentrations of bilirubin, and the same trend was observed also for BLVRA
(Table 3). These changes in mRNA expressions were, however, not translated onto increase of
Fig 6. The effect of bilirubin and bilirubin PI on the cell viability in our in vitromodel. (A) 24 hr exposure;
n = 7. (B) 48 hr exposure; n = 4. * p < 0.05 vs. control; # p < 0.05 vs. bilirubin. Cell viability tested by CellTiter-
Glo test; exactly the same results were obtained with MTT test. UCB, unconjugated bilirubin.
doi:10.1371/journal.pone.0148126.g006
Table 3. The effect of bilirubin and bilirubin PI on expression of selected genes.
Bilirubin 15% PI Bilirubin+15% PI
HMOX1 232.2 (197–240)* 105.6 (93–109) 277.1 (175–358)*
HMOX2 130.3 (129–166)* 84.8 (74–88) 100.3 (91–151)
BLVRA 142.9 (109–179) 86.3 (53–122) 158.4 (94–180)
MRP1 76.3 (71–90) 84.9 (51–100) 76.7 (61–89)
MDR1 54.9 (35–84) 86.3 (35–113) 87.3 (33–99)
Cyclin D1 71.8 (64–157) 64.5 (52–81)* 175.3 (137–232)*
Cyclin E 78.9 (50–126) 76.4 (59–84) 84.3 (77–106)
data are expressed as % of control (median and IQ range), n = 5 for each measurement. PI, bilirubin
photoisomers
* p < 0.05 vs. control
doi:10.1371/journal.pone.0148126.t003
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HMOX activity (data not shown). Interestingly, exposure to bilirubin PI did not lead to the
changes in mRNA expression profiles seen after exposure to bilirubin.
Additionally, no difference was found in the expressions of eitherMRP1 orMDR1—genes
coding transporting proteins responsible for export of multiple compounds also possibly
including bilirubin [43,44]. Expressions of genes encoding cyclins D1 and E involved in regu-
lating the G0 to S phase, and G1 to S phase transition, respectively [45,46] tended to be down-
regulated upon exposure to bilirubin and bilirubin PI (Table 3). Nevertheless, these mRNA
expression changes were not functionally translated, as evidenced by flow cytometry analysis of
the cell cycle phase of the SH-SY5Y cells exposed to bilirubin, bilirubin PI, or their mixture.
This analysis revealed that compared to control cells, treatments with studied pigments had no
effect on the cell cycle progression after either short or long exposure (data not shown).
Discussion
Phototherapy is a non-invasive and effective treatment for neonatal hyperbilirubinemia, as
well as one which facilitates the disposal of toxic bilirubin and avoids brain injury. Since its
development in the 1950’s, it has become a standard and widely available treatment for this
condition.
Phototherapy can reduce serum bilirubin by its conversion into its structural photoisomers
and photooxidation products, which are excreted from the human body without the need of
further biotransformation in the liver. It is generally believed that bilirubin photoisomers are
non-toxic; however, no clear evidence for this viewpoint exists, and insufficient data about bili-
rubin PI's biological effects have thus far been provided. [16–23]. Of note is the fact that in
none of these studies were the pure forms of the bilirubin photoderivatives used, most likely
because of their complicated isolation and handling. To the contrary, short-term as well as
long-term side effects of phototherapy have been repeatedly reported [7–12]; the mechanisms
of which are unclear and might theoretically be accounted for by the biological activities of bili-
rubin PI.
In our experiments, we were able to successfully separate 18 different bilirubin photoderiva-
tives generated during photo-irradiation of bilirubin solution. Out of these, we identified and
isolated the major bilirubin photoderivatives (ZE/EZ-bilirubin and lumirubin) in sufficient
purity and quantity for biological studies.
We were able to demonstrate that these bilirubin PI do not increase Bf levels, and thus do
not increase bilirubin toxicity per se. Lumirubin was found to have only one binding site on
HSA, and this binding site was the same as for hemin (i.e. in the subdomain IB or close to it).
Nevertheless, the bilirubin and lumirubin binding sites on albumin are not totally independent,
because the lumirubin binding site is close to the bilirubin high-affinity binding site; to a cer-
tain extent it is also able to lower bilirubin's ability to bind to HSA. However, this effect is prob-
ably not clinically relevant. In support of this data, we confirmed that lumirubin-HSA's
binding constant is much lower, compared to bilirubin. These data collectively demonstrate
that although lumirubin binds to albumin, the binding has no biological relevance in terms of
any possible influence on bilirubin-albumin binding.
The experiments, focused on the potential cytotoxicity of major bilirubin PI, revealed no
apparent effects on cell viability in our in vitromodel, even after prolonged exposure. This was
in striking contrast with the known toxic effects of bilirubin. This indicates that only unconju-
gated bilirubin is toxic, and that the conformational changes induced by irradiation almost
completely abolishes the noxious effects of the pigment on the cell.
Neither bilirubin, nor bilirubin PI had any functional effect on two key enzymes (HMOX
and BLVRA) important in heme degradation and bilirubin production. The lack of any effect
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of bilirubin PI on BLVRAmRNA expression was not expected, since biliverdin to some extent
is also produced during phototherapy [6]. Similar negative results of bilirubin/bilirubin PI
exposure were also found forMRP1 andMDR1mRNA gene expression, indicating that these
transporters are not inducible, at least in our cell system, by either bilirubin or their PI.
Our study has several limitations. First, we only assessed the biological effects of three major
bilirubin PI, ZE/EZ-bilirubins and Z-lumirubin, and thus we cannot exclude that other photo-
products or bilirubin oxidation products formed during phototherapy, especially those short-
lived and not detected in our study, might be toxic. Thus, it is still needed to be carefully
assessed, whether minor oxidation products produced from bilirubin during phototherapy can
exert any biological action. In addition, our studies were only performed on one cell line, repre-
senting a neuronal in vitromodel. However, other brain cells, such as astrocytes, microglia, or
even endothelial cells should also be tested; ideally in an organotypic brain slice ex vivomodel
to bring conclusive evidence.
In conclusion, our data indicate that the major bilirubin PI, ZE/EZ-bilirubin and lumirubin,
seem to be biologically inert, and do not exert any negative biological effects. The side effects of
phototherapy, theoretically attributable to bilirubin PI, are most likely due to other mechanisms.
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